

National Home Infusion Association

- **Trade association representing home infusion providers, suppliers, manufacturers, and distributors**
- **350+ member organizations**
- **~1000 individual pharmacy sites**
- **~11,000 clinicians**
- **3M patients receive home infusion annually**

Source: Infusion Industry Trends 2020, National Home Infusion Foundation



Home Infusion Services & Population

- Wide range of therapies for acute and chronic conditions can be infused at home
 - 10% of patients receive biologics
- Therapy duration ranges from 7 days to many years
- Spans all payer sources
 - 25% Medicaid population in small, single-site providers
- All age groups represented

Source: Infusion Industry Trends 2020, National Home Infusion Foundation



Bamlanivimab and Home Infusion

- One-time infusion makes it difficult to recover costs
 - Nursing time
 - Onboarding process
 - Supplies, drug preparation & delivery
 - Infusion reaction kits
- Not all patients have a referring physician
- No product allocation for home use
- Commercial payers and Medicaid plans have not established billing rates for administration
- Limited nursing availability



SPEED
Program:
NHIA
Bamlanivimab

Special Projects for Equitable and Efficient Distribution (SPEED)

Program Objectives

- Utilize NHIA relationships to identify home infusion providers to provide bamlanivimab and nursing support for LTC facilities
- Link capable, accredited providers with states for receiving further allocations, expanding access to under-served, high-risk populations

Pilot Process



SPEED NHIA-LTC Pilot Results

- 144 providers enrolled and credentialed as of 5/16/20
- 560 doses allocated in week 1
- Positive response from most providers, many requesting much larger allocations for week 2
- Interest is extending beyond LTC
 - Prisons
 - Dialysis centers
 - Home

The screenshot shows the NHIA (National Home Infusion Association) website. At the top is the NHIA logo and navigation links: Home, About Us, Learn, Advocate, About Infusion Therapy, News, Connect, NHIF, and Membership. A banner below the navigation bar reads: "STAY INFORMED. VISIT [NHIA.ORG/COVID19](https://nhia.org/covid19) FOR INFORMATION AND RESOURCES ABOUT CORONAVIRUS DISEASE (COVID-19)." Below the banner, there are two main sections. On the left, a dark blue box titled "COVID-19 RESOURCE CENTER" with a "Learn more >>" link. To its right, a blue box titled "STATE RESOURCES FOR HEALTH DEPARTMENTS" with a "Learn more >>" link. The main content area is titled "NHIA BAMLANIVIMAB PILOT PROGRAM". The text below the title states: "NHIA is working with the Department of Health and Human Services (HHS) to increase access to bamlanivimab (Eli Lilly) for COVID-19 in high-risk, eligible individuals residing or working in long-term care facilities, including assisted living facilities. The program utilizes home infusion providers – in partnership with facility staff – to identify, assess, coordinate, dispense, and administer monoclonal antibody therapies in these healthcare settings." It then mentions that home infusion providers who wish to participate will be listed on a publicly accessible database for states to reference for future COVID-19 treatment opportunities. At the bottom, it states: "The program is open to both NHIA member and non-member provider organizations, provided they qualify. In order to participate, a provider must:" followed by a bullet point: "• Be a licensed pharmacy in good standing".

NHIA
National Home Infusion Association

Join NHIA Today Access Member Portal

Home About Us Learn Advocate About Infusion Therapy News Connect NHIF Membership

STAY INFORMED. VISIT [NHIA.ORG/COVID19](https://nhia.org/covid19) FOR INFORMATION AND RESOURCES ABOUT CORONAVIRUS DISEASE (COVID-19).

COVID-19 RESOURCE CENTER
Learn more >>

STATE RESOURCES FOR HEALTH DEPARTMENTS
Learn more >>

NHIA BAMLANIVIMAB PILOT PROGRAM

NHIA is working with the Department of Health and Human Services (HHS) to increase access to bamlanivimab (Eli Lilly) for COVID-19 in high-risk, eligible individuals residing or working in long-term care facilities, including assisted living facilities. The program utilizes home infusion providers – in partnership with facility staff – to identify, assess, coordinate, dispense, and administer monoclonal antibody therapies in these healthcare settings.

Home infusion providers who wish to participate in the program and meet the eligibility criteria will be listed on a publicly accessible database for states to reference for future COVID-19 treatment opportunities.

The program is open to both NHIA member and non-member provider organizations, provided they qualify. In order to participate, a provider must:

- Be a licensed pharmacy in good standing